Keywords: Astellas, New mid-term plan, Emerging markets, China, Research
Astellas sets out goals as “category leader” in new mid-term plan, with focus on China
Article | 26 May 2010
Japanese drug major Astellas Pharma, which recently secured agreement from USA-based OSI Pharmaceuticals to proceed with its increased $4 billion bid ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
